Skip to main content

Table 4 Comparison of questions in AGREE II and iCAHE instruments relevant to domains

From: Efficient clinical evaluation of guideline quality: development and testing of a new tool

AGREE II Domain 1: Scope & Purpose Q13 Are the purpose and target users of the guideline stated? Q1. The overall objectives of the guideline are specifically described
  Q2. The health questions covered by the guideline are specifically described
  Q3. The population to whom the guideline is meant to apply is specifically described
  Q6. The target users are clearly defined
AGREE II Domain 2: Stakeholder involvement Q11. Are the developers clearly stated? Q4. The guideline development group includes individuals from all relevant professional groups
Q12. Does the qualifications and expertise of the guideline developers link with the purpose of the guideline and its end users? Q5. The views and preferences of the target population have been sought
  Q7. Does the guideline provide an outline of the strategy used to find underlying evidence? Q7. Systematic methods were used to search for the evidence
Q8. Does the guideline use a hierarchy to rank the quality of the underlying evidence? Q8. The criteria for selecting the evidence are clearly described
Q9. Does the guideline appraise the quality of the evidence which underpins its recommendations? Q9. The strengths and limitations of the body of evidence are clearly described
Q10. Does the guideline link the hierarchy and quality of underlying evidence to each recommendation? Q10. The methods for formulating the recommendations are clearly described
AGREE II Domain 3: Rigour of Development   Q11. The health benefits, side effects and risks have been considered in formulating the recommendations
  Q12. There is an explicit link between the recommendations and the supporting evidence
  Q13. The guideline has been eternally reviewed by experts prior to its publication
  Q14. A procedure for updating the guideline is provided
New iCAHE instrument Domain: Currency Q4. Is there a date of completion available?  
Q5. Does the guideline provide an anticipated review date?  
Q6. Does the guideline provide dates for when literature was included?  
AGREE II Domain 4: Clarity of Presentation Q14. Is the guideline readable and easy to navigate? Q15. The recommendations are specific and unambiguous
  Q16. The different options for management of the condition or health issues are clearly presented
  Q17. Key recommendations are easily identifiable
AGREE II Domain 5: Applicability   Q18. The guideline describes facilitators and barriers to its application
  Q19. The guideline provides advice and/or tools on how the recommendations can be put into practice
  Q20. The potential resources implications of applying the recommendations have been considered
   Q21. The guideline presents monitoring and/or auditing criteria
AGREE II Domain 6: Editorial Independence   Q22. The views of the funding body have not influenced the content of the guideline
  Q23. Competing interests of guideline development group members have been recorded and addressed
New iCAHE instrument Domain: Availability Q1. Is the guideline readily available in full text?  
Q2. Does the guideline provide a complete reference list?  
New iCAHE instrument Domain: Summary Q3. Does the guideline provide a summary of its recommendations?